Lintuzumab Ph IIb AMD trial completes enrollment

2 March 2009

US drug developer Seattle Genetics has completed patient enrollment in a Phase IIb trial of lintuzumab (SGN-33) in combination with low-dose  cytarabine chemotherapy for patients with acute myeloid leukemia.

"We are pleased to have achieved our enrollment goal of 210 patients in  this global Phase IIb trial in less than 18 months," said Thomas  Reynolds, chief medical officer of the firm. "This trial is designed to  determine if combining lintuzumab with a low-dose regimen of  chemotherapy extends survival in older AML patients, a setting where  there are limited treatment alternatives and patients have a median  survival of less than six months. We anticipate that data from the  trial, which is event-driven, will be available in the first half of  2010," he added.

The lintuzumab Phase IIb randomized, double-blind, placebo-controlled  study evaluating whether the combination regimen of lintuzumab and  low-dose cytarabine chemotherapy extends overall survival compared to  low-dose cytarabine alone in previously untreated AML patients age 60  and older who decline intensive chemotherapy. The primary endpoint of  the study, which is being conducted at more than 80 clinical sites  worldwide, is overall survival.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight